CSIMarket Company Name, Ticker, Industry, else..
 
Avid Bioservices Inc   (NASDAQ: CDMO)
 
Price: $12.4900 $0.01 0.080%
Day's High: $12.51 Week Perf: 0.4 %
Day's Low: $ 12.47 30 Day Perf:
Volume (M): 3,067,700 52 Wk High: $ 0.00
Volume (M$): $ 38,316 52 Wk Avg: $0.00
Open: $12.49 52 Wk Low: $0.00



 Market Capitalization (Millions $) 797
 Shares Outstanding (Millions) 64
 Employees 371
 Revenues (TTM) (Millions $) 151
 Net Income (TTM) (Millions $) -152
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 15

Business Description


Avid Bioservices Inc is a biopharmaceutical company based in California. They specialize in providing contract manufacturing services for the development and production of biologics, such as monoclonal antibodies and recombinant proteins. Avid Bioservices has state-of-the-art facilities and a team of experienced professionals to support their clients' drug development programs. They have a strong track record of successfully delivering high-quality products to the biotechnology and pharmaceutical industries.


   Company Address: 14191 Myford Road Tustin 92780 CA
   Company Phone Number: 508-6100   Stock Exchange / Ticker: NASDAQ CDMO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BPMC      % 
CTLT        0.38% 
IONS   -4.85%    
SRPT        7.86% 
STOK   -5.72%    
WVE   -3.57%    
• View Complete Report
   



Stock Market Announcement

Avid Bioservices Bold Step Forward: A New Era of Growth Following Stockholder Approval

Published Thu, Jan 30 2025 9:05 PM UTC

On January 30, 2025, Avid Bioservices, Inc. (NASDAQ: CDMO) took a significant step towards enhancing its position in the biologics contract development and manufacturing sector. During a special meeting, stockholders overwhelmingly approved a pivotal transaction involving GHO Capital Partners LLP (GHO) and Ampersand Capital Partners (Ampersand). This decision marks a major t...
Stock Market Announcement

Navigating New Frontiers: Avid Bioservices Strategic Acquisition Paves the Way for Growth in Biologics,

Published Wed, Feb 5 2025 3:45 PM UTC

Avid Bioservices Acquired by GHO Capital and Ampersand Capital Partners: Charting a Promising Path in Biologics ManufacturingIn an era where biotechnology continues to shape the future of medicine, Avid Bioservices, a prominent biologics contract development and manufacturing organization (CDMO), finds itself at the heart of a transformative acquisition. On February 5, 2025,...
Merger and Acquisition

Avid Bioservices Acquired by GHO Capital and Ampersand Capital Partners, Signaling Optimistic Growth Trajectory in Biologics Manufacturing Sector.

Published Wed, Feb 5 2025 2:55 PM UTC

Avid Bioservices Poised for Significant Growth with New Partners GHO Capital and Ampersand Capital PartnersIntroductionIn a major development for the biotechnology and pharmaceutical landscape, GHO Capital Partners LLP, a leading European investor focused on the global healthcare sector, has partnered with Ampersand Capital Partners, a private equity firm dedicated to growt...
Stock Market Announcement

Avid Bioservices Latest Transaction Secures Immediate Cash Gains for Shareholders Amid Strategic Partnerships

Published Wed, Jan 22 2025 9:05 PM UTC

In an unfolding narrative that continues to capture the attention of the investment community, Avid Bioservices has taken decisive steps to communicate the tangible benefits of its recent strategic partnerships. In a letter addressed to its stockholders, the biotechnology company emphasizes the significant, immediate, and certain cash value that a pivotal transaction deliver...
Stock Market Announcement

Avid Bioservices Urges Stockholders to Vote FOR GHO and Ampersand Deal as Independent Advisors Validate Strategic Cash Value Benefits,

Published Tue, Jan 21 2025 1:01 PM UTC

Avid Recommends Stockholders Follow Recommendations of ISS and Glass Lewis and Vote FOR the Transaction with GHO and AmpersandIn a recent comprehensive press release, Avid Bioservices Inc. has strongly urged its stockholders to heed the guidance of leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass Lewis, and to vote in favor of the ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 5.30
Price to Sales (Expected) -
Price to Book 17.79
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.45
Working Capital Ratio 1.3
Leverage Ratio (MRQ) 6.22
Total Debt to Equity 3.44
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.4 $
Revenues (TTM) 2.36 $
Cash Flow (TTM) 0.03 $
Cash 0.52 $
Book Value 0.7 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 405,763
Net Income per Employee (TTM) -409,838
Receivable Turnover Ratio (TTM) 8.08
Inventory Turnover Ratio (TTM) 4.55
Asset Turnover Ratio (TTM) 0.47

Profitability Ratios Current
Gross Margin (MRQ) -6.11 %
Operating Margin (MRQ) -37.72 %
Net Margin (MRQ) -51.99 %
Net Cash Flow Margin (MRQ) 0.1 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Avid Bioservices Inc's Segments
Manufacturing Revenues    81.46 % of total Revenue
Process Development Revenues    18.54 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.